$GOVX
GeoVax Labs, Inc. Stock $govx

$govx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000143774923007636 Filed on March 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$81.53K
YoY Change	-100.0%	-100.0%	-78.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.451M	$1.623M	$4.987M
YoY Change	23.1%	59.97%	39.4%
% of Gross Profit
Research & Development	$2.819M	$3.765M	$9.123M
YoY Change	111.88%	-70.8%	-41.34%
% of Gross Profit
Depreciation & Amortization	$17.32K	$14.07K	$56.28K
YoY Change	41.16%	20.15%	46.11%
% of Gross Profit
Operating Expenses	$4.271M	$5.388M	$14.11M
YoY Change	70.17%	-61.27%	-26.25%
Operating Profit	-$4.271M		-$14.03M
YoY Change	75.89%		-25.16%
Interest Expense	$232.7K	$3.690K	$0.00
YoY Change		398.65%	-100.0%
% of Operating Profit
Other Income/Expense, Net			$7.439K
YoY Change			-95.76%
Pretax Income	-$4.038M	-$5.384M	-$14.02M
YoY Change	66.34%	-60.83%	-24.5%
Income Tax
% Of Pretax Income
Net Earnings	-$4.038M	-$5.384M	-$14.02M
YoY Change	66.34%	-60.83%	-24.5%
Net Earnings / Revenue			-17198.35%
Basic Earnings Per Share	-$0.15		-$0.83
Diluted Earnings Per Share	-$0.15	-$0.20	-$0.83
COMMON SHARES
Basic Shares Outstanding	26.33M	26.33M	16.97M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.85M	$27.61M	$27.61M
YoY Change	46.7%	141.71%	141.71%
Cash & Equivalents	$23.85M	$27.61M	$27.61M
Short-Term Investments
Other Short-Term Assets	$2.139M	$1.326M	$1.326M
YoY Change	664.87%	748.69%	748.69%
Inventory
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$25.99M	$28.94M	$28.94M
YoY Change	56.21%	148.85%	148.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$217.6K	$234.9K	$234.9K
YoY Change	5.19%	49.68%	49.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.198M	$2.174M	$2.174M
YoY Change	10779.09%	19648.28%	19648.32%
Total Long-Term Assets	$1.415M	$2.409M	$2.409M
YoY Change	549.66%	1334.49%	1334.56%
TOTAL ASSETS
Total Short-Term Assets	$25.99M	$28.94M	$28.94M
Total Long-Term Assets	$1.415M	$2.409M	$2.409M
Total Assets	$27.40M	$31.35M	$31.35M
YoY Change	62.59%	165.73%	165.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.288M	$1.748M	$1.748M
YoY Change	202.27%	-15.06%	-15.06%
Accrued Expenses	$3.251M	$3.000M	$3.000M
YoY Change	5.73%	-11.18%	-11.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.539M	$4.748M	$4.748M
YoY Change	29.65%	-12.65%	-12.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.539M	$4.748M	$4.748M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$4.539M	$4.748M	$4.748M
YoY Change	-17.49%	-36.14%	-36.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$82.43M	-$78.40M
YoY Change	23.4%	21.78%
Common Stock	$105.3M	$105.0M
YoY Change	34.73%	52.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.87M	$26.60M	$26.60M
YoY Change
Total Liabilities & Shareholders Equity	$27.40M	$31.35M	$31.35M
YoY Change	62.59%	165.73%	165.73%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$4.038M	-$5.384M	-$14.02M
YoY Change	66.34%	-60.83%	-24.5%
Depreciation, Depletion And Amortization	$17.32K	$14.07K	$56.28K
YoY Change	41.16%	20.15%	46.11%
Cash From Operating Activities	-$3.763M	-$7.064M	-$19.03M
YoY Change	-13.16%	5.7%	69.97%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$134.3K
YoY Change	-100.0%		181.36%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$134.3K
YoY Change	-100.0%		181.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	0.000	$35.35M
YoY Change	-100.0%		176.54%
NET CHANGE
Cash From Operating Activities	-$3.763M	-7.064M	-$19.03M
Cash From Investing Activities	$0.00	0.000	-$134.3K
Cash From Financing Activities	$0.00	0.000	$35.35M
Net Change In Cash	-$3.763M	-7.064M	$16.19M
YoY Change	-177.84%	5.7%	951.17%
FREE CASH FLOW
Cash From Operating Activities	-$3.763M	-$7.064M	-$19.03M
Capital Expenditures	$0.00	$0.00	$134.3K
Free Cash Flow	-$3.763M	-$7.064M	-$19.16M
YoY Change	-14.39%	5.7%	70.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000832489
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000832489
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	13239406	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	26334953
CY2022	dei	Auditor Firm AuditorFirmId	344
CY2022	dei	Auditor Name AuditorName	WIPFLI LLP
CY2022	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27612732	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11423870	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	0	usd
CY2021Q4	us-gaap	Grants Receivable GrantsReceivable	49006	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1325998	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	156240	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	28938730	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	11629116	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	234912	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156938	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2174286	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11010	usd
CY2022Q4	us-gaap	Assets Assets	31347928	usd
CY2021Q4	us-gaap	Assets Assets	11797064	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1747682	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2057534	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3000212	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3377826	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4747894	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5435360	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	4747894	usd
CY2021Q4	us-gaap	Liabilities Liabilities	7435360	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26334953
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26334953
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6381541
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6381541
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	26335	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6382	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	104970722	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	68731220	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78397023	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64375898	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26600034	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4361704	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31347928	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11797064	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	81526	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	385501	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9123479	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15554171	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-14028564	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-18745823	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	4736	usd
CY2022	us-gaap	Interest Expense InterestExpense	-0	usd
CY2021	us-gaap	Interest Expense InterestExpense	1286	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	172056	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14021125	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.04
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16973194
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6099933
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	9568852	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9408920	usd
CY2021	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	3404156	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	71841	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	209825	usd
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	269427	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-18570317	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4361704	usd
CY2022	govx	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	7626134	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	132750	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	773377	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14021125	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26600034	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14021125	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	56284	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38521	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	902074	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	369987	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	209825	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	172056	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-49006	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-133657	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1165705	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	16270	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2163276	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-0	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2687466	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6810233	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-5009083	usd
CY2021	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	7373897	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19030208	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11196420	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	134258	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47718	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-134258	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47718	usd
CY2022	govx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	27727194	usd
CY2021	govx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	9408920	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7626134	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3404156	usd
CY2022	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	-0	usd
CY2021	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	1000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	27864	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35353328	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12784212	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16188862	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1540074	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11423870	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9883796	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27612732	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11423870	usd
CY2021	govx	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	149705
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"> <tbody><tr style="vertical-align: top;"> <td style="width: 36pt;"> <p style="margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b>1.</b></p> </td> <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><b>Description of Business and Recent Developments</b></p> </td> </tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc., headquartered in the Atlanta, Georgia metropolitan area, is a clinical-stage biotechnology company incorporated under the laws of the State of Delaware. GeoVax Labs, Inc. and its wholly owned subsidiary, GeoVax, Inc., a Georgia corporation, are collectively referred to herein as “GeoVax” or the “Company”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is focused on developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax’s product pipeline includes ongoing human clinical trials for vaccines against COVID-19 and a therapy for advanced head and neck cancer. Additional research and development programs include preventive vaccines against hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa Fever) Zika virus, and malaria, as well as immunotherapies for solid tumors.</p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<i>Use of Estimates</i>The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15442915
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3778931
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<i>Period-to-Period Comparisons</i>Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2174286	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11010	usd
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022Q4	govx	Prepaid Clinical Trial Expenses Current PrepaidClinicalTrialExpensesCurrent	1171077	usd
CY2021Q4	govx	Prepaid Clinical Trial Expenses Current PrepaidClinicalTrialExpensesCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	107876	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	123248	usd
CY2022Q4	us-gaap	Prepaid Rent PrepaidRent	13045	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	13045	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	19947	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1325998	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	156240	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	841417	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	707159	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	606505	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	550221	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	234912	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	156938	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	56284	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38521	usd
CY2022Q4	govx	Prepaid Clinical Trial Expenses Noncurrent PrepaidClinicalTrialExpensesNoncurrent	2083276	usd
CY2021Q4	govx	Prepaid Clinical Trial Expenses Noncurrent PrepaidClinicalTrialExpensesNoncurrent	0	usd
CY2022Q4	govx	Prepaid Technology License Fees PrepaidTechnologyLicenseFees	80000	usd
CY2021Q4	govx	Prepaid Technology License Fees PrepaidTechnologyLicenseFees	0	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	11010	usd
CY2021Q4	us-gaap	Security Deposit SecurityDeposit	11010	usd
CY2022Q4	govx	Accrued License Fees Current AccruedLicenseFeesCurrent	2000000	usd
CY2021Q4	govx	Accrued License Fees Current AccruedLicenseFeesCurrent	3000000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	550810	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	269000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	449402	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	108826	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3000212	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	3377826	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	2000000	usd
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1644000
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9400000	usd
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	143500
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	13707
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15459615
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	962300
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	499660	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1096500
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.76
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2058800
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.89
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	588089
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.12
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13384115
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0354	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0143	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.600	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.848	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.73
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.87
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1449405	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2022Q4	govx	Prepaid Expense Value Of Stock Issued For Services During Period PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod	24000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	902074	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	369987	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	53643	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	36980	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19764569	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	18449694	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2202603	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1566293	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	330553	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	129475	usd
CY2022Q4	govx	Deferred Tax Assets Accrued Salaries DeferredTaxAssetsAccruedSalaries	663211	usd
CY2021Q4	govx	Deferred Tax Assets Accrued Salaries DeferredTaxAssetsAccruedSalaries	69940	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22960936	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20215402	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	51466	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	30945	usd
CY2022Q4	govx	Deferred Tax Assets Before Valuation Allowance Net DeferredTaxAssetsBeforeValuationAllowanceNet	22909470	usd
CY2021Q4	govx	Deferred Tax Assets Before Valuation Allowance Net DeferredTaxAssetsBeforeValuationAllowanceNet	20184457	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22909470	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20184457	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.040	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.002	pure
CY2022	govx	Effective Income Tax Rate Reconciliation Nol Carryforward Expiration Percent EffectiveIncomeTaxRateReconciliationNOLCarryforwardExpirationPercent	-0.156	pure
CY2021	govx	Effective Income Tax Rate Reconciliation Nol Carryforward Expiration Percent EffectiveIncomeTaxRateReconciliationNOLCarryforwardExpirationPercent	-0.053	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.046	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.020	pure
CY2022	govx	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance And Other Adjustments Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceAndOtherAdjustmentsPercent	-0.139	pure
CY2021	govx	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance And Other Adjustments Percent EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowanceAndOtherAdjustmentsPercent	-0.219	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure

Files In Submission

Name	View Source	Status
0001437749-23-007636-index-headers.html	Edgar Link	pending
0001437749-23-007636-index.html	Edgar Link	pending
0001437749-23-007636.txt	Edgar Link	pending
0001437749-23-007636-xbrl.zip	Edgar Link	pending
ex_489503.htm	Edgar Link	pending
ex_489503img001.jpg	Edgar Link	pending
ex_489504.htm	Edgar Link	pending
ex_489504img002.jpg	Edgar Link	pending
ex_489505.htm	Edgar Link	pending
ex_489506.htm	Edgar Link	pending
ex_489507.htm	Edgar Link	pending
ex_489508.htm	Edgar Link	pending
ex_489509.htm	Edgar Link	pending
ex_489510.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
govx-20221231.xsd	Edgar Link	pending
govx20221231_10k.htm	Edgar Link	pending
govx20221231_10kimg001.jpg	Edgar Link	pending
jtsig.jpg	Edgar Link	pending
logo.jpg	Edgar Link	pending
logo2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrsig.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
govx-20221231_pre.xml	Edgar Link	unprocessable
govx-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
govx-20221231_cal.xml	Edgar Link	unprocessable
govx-20221231_def.xml	Edgar Link	unprocessable
govx20221231_10k_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GOVX
GeoVax Labs, Inc. Stock $govx

2023 Q1 Form 10-K Financial Statement

#000143774923007636 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOVX GeoVax Labs, Inc. Stock $govx

2023 Q1 Form 10-K Financial Statement

#000143774923007636 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GOVX
GeoVax Labs, Inc. Stock $govx